PS
PeptideScholar

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Tirzepatide

AFDA Approved

Dual GIP/GLP-1 receptor agonist · 39 amino acids · Brand: Mounjaro, Zepbound

FDA ApprovedPrescription Required

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.

Mechanism of Action

Simultaneously activates GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and reducing appetite. The dual agonism provides additive metabolic benefits.

Benefits

  • Up to 22.5% mean body weight loss (SURMOUNT-1)
  • Superior HbA1c reduction vs semaglutide (SURPASS-2)
  • Improved insulin sensitivity
  • Reduced cardiovascular risk factors
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Tirzepatide — Dosing in Published Research

Reported Routes: Subcutaneous injection
Titrated from 2.5 mg SC weekly, increasing in 2.5 mg increments every 4 weeks to 5, 10, or 15 mg weekly.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Nausea and vomiting
  • Diarrhea
  • Decreased appetite
  • Constipation
  • Injection site reactions

Ready to Discuss Tirzepatide with a Doctor?

Tirzepatide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Find a Prescribing Provider

Telehealth consultations available in most states

FDA ApprovedBoard-Certified DoctorsPrescription if Appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Research & Evidence

RCTNew England Journal of Medicine, 2022

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Tirzepatide produced mean weight reductions of 15-22.5% at 72 weeks across dose groups vs 3.1% with placebo

PMID: 35658024
RCTNew England Journal of Medicine, 2021

Tirzepatide versus Semaglutide in Type 2 Diabetes (SURPASS-2)

Tirzepatide at all doses was superior to semaglutide 1 mg for HbA1c reduction and weight loss

PMID: 34170647

Compare Tirzepatide With

Tirzepatide vs Semaglutide
Tirzepatide vs AOD-9604
Tirzepatide vs Tesamorelin
Tirzepatide vs Retatrutide
Tirzepatide vs Liraglutide
Tirzepatide vs Survodutide

References

  1. 1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. “Tirzepatide produced mean weight reductions of 15-22.5% at 72 weeks across dose groups vs 3.1% with placebo” [PMID: 35658024]
  2. 2. Tirzepatide versus Semaglutide in Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021. “Tirzepatide at all doses was superior to semaglutide 1 mg for HbA1c reduction and weight loss” [PMID: 34170647]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.